Statins
Previous studies in mice have demonstrated statins reduce CiO. Their
effect was tested on 277 adults (546 ears) treated with cisplatin and
concurrent radiotherapy for head and neck cancer in an observational
study. Of the 6 types of statins tested in this observational study,
44% of patients took atorvastatin. The mixed-effect model analysis
showed atorvastatin was significantly associated with reduced cisplatin
hearing loss (P ≤ 0.01) (OR = 0.47; 95% CI, 0.30–0.78). No significant
correlation was found between high-frequency hearing loss and
atorvastatin dose. Adverse effects were not reported (Fernandez et al.,
2021).
Table 3. Characteristics of the studies assessing pharmacological
interventions.